Docking of proteasome inhibitors for multiple myeloma using transcriptomic-guided selection.
Thu, 24 Apr
|On Going Project
This study proposes a transcriptomic-guided approach to identify patient-specific or highly effective proteasome inhibitors using molecular docking, aiming for precision-targeted therapy.
Time & Location
24 Apr 2025, 7:00 pm – 11:00 pm
On Going Project
About the event
Background:
Multiple myeloma is a hematologic cancer characterized by the clonal proliferation of malignant plasma cells in the bone marrow. The ubiquitin-proteasome pathway is essential for protein homeostasis, and its dysregulation plays a central role in MM pathogenesis. Proteasome inhibitors, such as bortezomib and carfilzomib, disrupt this pathway, inducing apoptosis in MM cells. However, resistance, toxicity, and varying patient response limit their efficacy.
Transcriptomic-Guided Drug Selection:
With the advent of high-throughput RNA sequencing, transcriptomic data allows a deeper understanding of gene expression profiles in MM patients. This research uses transcriptomic datasets to:
Identify overexpressed or underexpressed genes linked to proteasome activity and MM progression.
Highlight possible mutations or expression patterns that confer drug resistance or sensitivity.